Therapeutic area data reported by biopharma companies on phase I trials in March 2020, including: Actinium, Allergan, Aptevo, Aravive, Arrowhead, Artugen, Asana, Biocryst, Biomx, Bolt, Cabaletta, CNS, Cohbar, Compugen, Cyclo, Cytodyn, Dare, Debiopharm, Decibel, Discgenics, Dynacure, Enlivex, Eton, Evelo, Faron, Fulcrum, Gemoab, Genetx, Gilead Sciences, GT, Imcheck, Immutep, Inflarx, Inflazome, Inmed, Innate, Kancera, Kiniksa, Lattice, Matinas, Medivir, Mersana, Mina, Moderna, Novartis, Oncolytics, Oncopeptides, Oncternal, Orchard, Pliant, Prevail, Psioxus, Redhill, Seelos, Synlogic, Targovax, Terns, Tolero, Uniqure.

Therapeutic area data reported by biopharma companies on phase II trials in March 2020, including: Acceleron, Akero, Albireo, Algernon, Allakos, Axsome, Can-Fite, Cellphire, Chugai, Cortexyme, Cytodyn, Delmar, Diffusion, Engage, Genfit, Hansa, Horizon, Ideaya, Immutep, Innovent, Inovio, Irlab, ISA, Leading, Matinas, Mediwound, Moderna, Nantkwest, Neuraly, Obseva, Oncolys, Oncoquest, Opthea, Orchard, Orphomed, Orthotrophix, Ovid, Palvella, Phasebio, Proqr, Qurient, Redhill, Regeneron, Revive, Sanofi, Santen, Seres, Synlogic, Tenax, Theralase, Theranexus, Tracon, Uniqure, Vaccitech, Vivoryon, Xenon, Zealand.

During the first quarter of 2020, a total of 153 financings brought $13.2 billion into the med-tech industry, representing a 20% drop from the first quarter of 2019, but still significantly above all of the other quarters since 2017. The number of private financings appears to be climbing in comparison with recent years, and some large notes offerings have placed private raises of public companies on top. In contrast, IPOs and follow-on offerings are way down from previous quarters.

With nearly a quarter of the activity announced in March focused on COVID-19, the first quarter of 2020 appears to be on target to beat the deal and M&A values of two of the last three years, although it remains behind 2019. Despite the uncertainty of the coronavirus pandemic, let alone the upcoming U.S. presidential election, the industry has fared relatively well in terms of dealmaking so far this year, even as the markets have plummeted and partnering events have moved to a virtual format. In fact, deals should logically increase as the pandemic takes its toll on the economy, according to a biopharma executive who responded to a recent J.P. Morgan survey.

Although public offerings slowed considerably in March as a result of the steepest stock market declines in history during that period, global biopharmaceutical companies managed to collectively generate just over $16 billion in the first quarter from a record number public and private transactions. Only the first quarter of 2018 saw more cash raised in the past decade, according to BioWorld data.